Default: European Neuropsychopharmacology

ISSN: 0924-977X

Journal Home

Journal Guideline

European Neuropsychopharmacology Q1 Unclaimed

Elsevier Netherlands
Unfortunately this journal has not been claimed yet. For this reason, some information may be unavailable.

European Neuropsychopharmacology is a journal indexed in SJR in Pharmacology and Neurology (clinical) with an H index of 124. It has an SJR impact factor of 1,442 and it has a best quartile of Q1. It is published in English. It has an SJR impact factor of 1,442.

European Neuropsychopharmacology focuses its scope in these topics and keywords: functioning, dopamine, drug, early, system, neuronal, response, patients, binding, calendar, ...

Type: Journal

Type of Copyright:

Languages: English

Open Access Policy: Open Choice

Type of publications:

Publication frecuency: -


European Neuropsychopharmacology


SJR Impact factor


H Index


Total Docs (Last Year)


Total Docs (3 years)


Total Refs


Total Cites (3 years)


Citable Docs (3 years)


Cites/Doc (2 years)




No comments ... Be the first to comment!

Aims and Scope

functioning, dopamine, drug, early, system, neuronal, response, patients, binding, calendar, clinical, receptor, monoamine, ambiguouscue, aripiprazolethe, angiotensinconverting, anchored, alzheimer’s, alters, allosteric, allocation, alcoholrelated, alcohol, aggression, adult, adiponectin,

Best articles by citations

Tryptophan depletion and neurohormonal regulation in remitted patients with seasonal affective disorder

View more

P.1.005 Trazodone and priapism

View more

P.1.010 MAO-A and MAO-B differ in their stereoselective biotransformation of citalopram in human liver

View more

P.1.026 An open study with sertraline in outpatients with dysthymia

View more

P.1.036 Efficacy of the association selective serotonin reuptake inhibitors + benzamides in the treatment of dysthymia

View more

P.1.041 Effect of pindolol in hastening response to serotoninergic antidepressants: An open study in severely depressed female in-patients

View more

P.1.048 Effects of first-trimester fluoxetine exposure on the newborn

View more

P.1.054 Combined antidepressant therapy using mirtazapine and citalopram in therapy resistent depression

View more

P.1.062 Patient-rated improvements for sertraline non-responders treated with fluoxetine

View more

P.1.063 A comparative study of sertraline vs. imipramine in post-psychotic depressive disorder of schizophrenia

View more

P.1.079 The pharmacological profile of venlafaxine, a new antidepressant drug given acutely and chronically

View more

Effect of nicotine on sniffing induced by dopaminergic receptor stimulation

View more

P.1.093 Trends in treating bipolar disorder during the last six years at a university clinic in Turkey

View more

P.1.098 Early phase II results of the RIMA RS-8359

View more

P.1.105 Does a lower initial starting dosage improve tolerability for once-daily venlafaxine XR?

View more

P.1.111 Relationships between selected immunological parameters and cortisol in treatment resistant depression

View more

P.1.119 Adjunctive long term treatment of therapy resistant circular psychoses with flupentixoldecanoat

View more

Prevalence and characteristics of patients with pseudoakathisia

View more

P.1.149 Neuroendocrine responses to the citalopram challenge test in major depression

View more

P.1.155 Steroid-independent translocation of the glucocorticoid receptor by the antidepressant, desipramine

View more

P.1.161 Treatment of atypical depression with sertraline: A double-blind comparative trial with moclobemide

View more

L-5 Critical progress in MAO inhibition in the treatment of mood disorders

View more

P.1.167 Citalopram in the treatment of depression in patients suffering from simultaneous serious somatic disorders

View more

P.1.172 Social aspects of mild antidepressants therapy of youth depressions accompanied by drug use

View more